Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Monkeypox Vaccination and Therapeutics
share announcement

Monkeypox Vaccination and Therapeutics

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 1909

Special Issue Editors

Dr. Mana Rao

E-Mail
Guest Editor
1. Essen Medical Associates, The Bronx, New York, NY 10453, USA
2. ArchCare, New York, NY 10016, USA
Interests: COVID-19; influenza; respiratory viral infections; viral diseases
Dr. Amesh Adalja

E-Mail Website
Guest Editor
School of Public Health, Johns Hopkins University, Baltimore, MD, USA
Interests: biosecurity; emerging infectious diseases; health security

Special Issue Information

Dear Colleagues,

Monkeypox wreaked global havoc amid the Coronavirus disease of 2019 (COVID-19) pandemic. While avoiding contact with infectious sources remains paramount for infection prevention, vaccines directed against the Monkeypox virus have been added as a tool in our armament of defences against Monkeypox. The aims of vaccination include pre-exposure prophylaxis for at-risk individuals. Novel strategies being applied include post-exposure prophylaxis (PEP) and expanded post-exposure prophylaxis, also known as PEP ++, with the hope to curb disease transmission and decrease morbidity. 

The aim of this Special Issue is to feature articles that focus on the 2022 Monkeypox public health emergency, including, but not limited to, vaccination, pre-exposure prophylaxis, post-exposure prophylaxis, expanded post-exposure prophylaxis (PEP ++) and use of antiviral agents. Original articles, reviews, short communications, and commentaries are welcome. 

Dr. Mana Rao
Dr. Amesh Adalja
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • monkeypox
  • monkeypox vaccination
  • antivirals

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 598 KiB  
Article
Safety of Monkeypox Vaccine Using Active Surveillance, Two-Center Observational Study in Italy
by Marco Montalti, Zeno Di Valerio, Raffaella Angelini, Elena Bovolenta, Federica Castellazzi, Marta Cleva, Paolo Pandolfi, Chiara Reali, Davide Resi, Renato Todeschini and Davide Gori
Vaccines 2023, 11(7), 1163; https://doi.org/10.3390/vaccines11071163 - 27 Jun 2023
Cited by 7 | Viewed by 1606
Abstract
In August 2022, Italy launched a vaccination campaign to combat the spread of the monkeypox virus, which the WHO has designated as a public health emergency. Priority targets for the campaign included laboratory personnel and men who have sex with men with specific [...] Read more.
In August 2022, Italy launched a vaccination campaign to combat the spread of the monkeypox virus, which the WHO has designated as a public health emergency. Priority targets for the campaign included laboratory personnel and men who have sex with men with specific risk criteria. Primary immunization involved two doses of the Imvanex/Jynneos vaccine, followed by a single booster dose. We conducted a study in two Italian towns, Bologna and Forlì, in October and November 2022 to investigate adverse events following immunization (AEFIs) of the monkeypox vaccine through participant-based active surveillance. Participants who received the vaccine and were aged 18 and over were invited to complete an e-questionnaire by scanning a QR code during their second vaccine appointment or by email one month after the booster dose. A descriptive analysis of AEFI incidences was conducted, with the results stratified by type and severity of symptoms. A total of 135 first-dose, 50 second-dose, and 6 single-dose recipients were included, with a mean age of 36.4 ± 8.7 years. Systemic reactions after the first and second doses were reported by 39.3% and 26.0% of participants, respectively, with asthenia being the most common symptom. Local site reactions were reported by 97.0% and 100.0% of participants, respectively, with redness, swelling, and itching being the most common local AEFIs. Grade 3 or 4 AEFIs were reported for local AEFIs only by 16.8% and 14.0% of participants after the first and second doses, respectively. Our findings suggest that the monkeypox vaccine has a high tolerability profile in terms of short-term common systemic AEFIs. However, the high incidence and severity of local AEFIs highlight the need to monitor their persistence following intradermal administration of the vaccine. Full article
(This article belongs to the Special Issue Monkeypox Vaccination and Therapeutics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop